Citadel Advisors
NGNE icon

Citadel Advisors’s Neurogene NGNE Stock Holding History

Citadel Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$224K Buy
+11,100
New +$215K ﹤0.01% 11179
2025
Q2 		– Sell
-10,000
Closed -$117K – 14200
2025
Q1 		$117K Sell
10,000
-28,500
-74% -$495K ﹤0.01% 11245
2024
Q4 		$880K Buy
+38,500
New +$1.43M ﹤0.01% 7314
2022
Q1 		– Sell
-515
Closed -$50K – 14247
2021
Q4 		$50K Buy
+515
New +$62.7K ﹤0.01% 13251
2021
Q3 		– Sell
-7,290
Closed -$1.35M – 14370
2021
Q2 		$1.35M Sell
7,290
-40
-0.5% -$8.85K ﹤0.01% 7571
2021
Q1 		$1.8M Buy
7,330
+1,950
+36% +$498K ﹤0.01% 6645
2020
Q4 		$1.52M Buy
+5,380
New +$1.31M ﹤0.01% 5947
2019
Q1 		– Sell
-1,685
Closed -$73K – 9667
2018
Q4 		$73K Sell
1,685
-5,095
-75% -$248K ﹤0.01% 8382
2018
Q3 		$397K Sell
6,780
-2,450
-27% -$145K ﹤0.01% 7088
2018
Q2 		$489K Buy
9,230
+8,105
+720% +$2.11M ﹤0.01% 6414
2018
Q1 		$317K Buy
+1,125
New +$311K ﹤0.01% 6658

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Citadel Advisors's NGNE Position: Q1 2026 in Review

Citadel Advisors increased its Neurogene (NGNE) stake by 6.3% in Q1 2026, buying an estimated $442K and bringing the position to 387,031 shares worth $7.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3616.

Citadel Advisors first reported a position in NGNE in Q3 2017 and has held it in 21 quarters since. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Citadel Advisors held 387,031 shares of Neurogene worth $7.8M as of Q1 2026.
  • Citadel Advisors bought 22,803 Neurogene shares in Q1 2026, an estimated $442K.
  • Neurogene made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3616 holding.
  • Citadel Advisors first reported a position in Neurogene in Q3 2017 and has held it in 21 quarters since.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.